PSC
AYTU icon

Piper Sandler & Co’s AYTU BioPharma AYTU Stock Holding History

Piper Sandler & Co’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,480
Closed -$297K – 36
2021
Q4 		$297K Buy
+2,480
New +$107K 0.21% 18
2021
Q1 		– Sell
-2,480
Closed -$297K – 19
2020
Q4 		$297K Buy
+2,480
New +$452K 0.21% 18

Other funds holding AYTU

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Piper Sandler & Co's AYTU Position: Q1 2022 in Review

Piper Sandler & Co sold out of AYTU BioPharma (AYTU) in Q1 2022, closing a stake of 2,480 shares — an estimated $297K sold.

Piper Sandler & Co first reported a position in AYTU in Q4 2020 and held it in 2 quarters. The position peaked at $297K in Q4 2021. 32 funds tracked by Wall St. Rank hold AYTU as of Q1 2022.

  • Piper Sandler & Co reported no remaining AYTU BioPharma position as of Q1 2022 after selling out during the quarter.
  • Piper Sandler & Co sold 2,480 AYTU BioPharma shares in Q1 2022, an estimated $297K.
  • Piper Sandler & Co first reported a position in AYTU BioPharma in Q4 2020 and held it in 2 quarters.
  • Piper Sandler & Co's AYTU BioPharma position peaked at $297K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2022.

Based on Piper Sandler & Co's 13F filing for Q1 2022, filed 13 May 2022.